Managing Toxicities with Tucatinib in Patients with HER2+ mCRC

Video

Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
5 experts in this video
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Related Content